BioSpace News Archive

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the external Data and Safety Monitoring Board (“DSMB”) has completed its latest review of the Phase 2b part of the Company’s Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, and has provided approval for the Company to continue on with the Phase 3 part of the study.

Healthcare Industry Veteran to Lead Blink Science Efforts in Developing the World’s First Instant COVID POC Diagnostic Testing Device and Launching a Comprehensive Electronic Medical Passport

AgBiome, a leader in developing innovative products from the Earth’s microbial communities, announced Dr. Marijn Dekkers as the company’s Chairman, effective January 1, 2021.

A senior secured term loan will support the further development of VERO Biotech’s GENOSYL® Delivery System, a proprietary tankless and portable delivery system for the administration of GENOSYL® (nitric oxide) gas, for inhalation

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the first patient has been dosed in a Phase 1/2 study evaluating the investigational agent TP-0184, an activin receptor-like kinase 2 (ALK2) and ALK5 inhibitor, for the treatment of anemia in adult patients with low or intermediate risk myelodysplastic syndromes (MDS).

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, announced that it will host a Key Opinion Leader symposium and pipeline update on Tuesday, January 26, 2021 at 11am Eastern Time.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has entered into a definitive agreement to acquire Mesa Biotech, Inc., a privately held molecular diagnostic company, for approximately $450 million in cash

Ace Vision Group, Inc, an emerging ophthalmic laser device company focused on bringing innovative touchless Eye Laser Therapy to patients suffering from age related vision loss, announced that it closed a Series A preferred stock round totaling $13.3M, which is $3.3M oversubscribed.

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the publication of an abstract for a research snapshot presentation to be presented as part of the Society of Critical Care Medicine’s (SCCM) 50th Annual Critical Care Congress being held virtually Jan. 31 through Feb. 12, 2021.

Acquisition establishes RealSelf’s position as the marketplace leader for English and Arabic speakers, furthering RealSelf’s vision of making every investment in modern beauty worth it